What does Definitive do and what are its main business segments?

What is the market's earnings forecast for Definitive next quarter?

What were the key takeaways from Definitive’s earnings call?

Did Definitive beat or miss consensus estimates last quarter?

What guidance did Definitive's management provide for the next earnings period?

What is Definitive's latest dividend and current dividend yield?

What is Definitive's gross profit margin?

What were the key takeaways from Definitive's earnings call?

- **Revenue stabilization**: Q3 $60M (-4% YoY) with enterprise customers up 10% QoQ, driven by claims data wins. 
- **Cost efficiency**: $2.5M savings from data renegotiations, 12-month free cash flow $51M. 
- **Digital growth**: 8 new agencies, $1M+ hospital expands from pilot to full campaign. 
- **2026 outlook**: EBITDA $68-69M (28% margin), cautious on life sciences renewals.

**【CEO Summary Section】**
- Q3 revenue of $60 million (-4% YoY) reflects stabilization in renewal rates and new logo growth, with enterprise customers up to 520 (highest since Q3 2024). 
- Competitive wins driven by differentiated claims data (e.g., biopharma client automating KOL identification, medical device firm leveraging affiliation hierarchies). 
- $2.5M cost savings from data source renegotiations, with new claims data source to launch in Q4. 
- Digital activation momentum: 8 new agencies signed, $1M+ hospital expands from pilot to full campaign.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $18.9M (32% margin) vs. $16M guidance, driven by $1.5M one-time data contract benefit. 
- 12-month unlevered free cash flow of $51M, with $9M share buybacks under $49M remaining authorization. 
- Q4 guidance: Revenue $59-60M (-4-5% YoY), EBITDA $16-17M (27% margin). 
- 2025 full year adj. EBITDA $68-69M (28% margin), up $3M from prior guide. 
- Gross margin pressure from $2M one-time data source credits in Q2/Q3, offset by $1M run-rate savings.

**【Q&A Highlights】**
- **New logo strength**: 2,400 total customers (flat QoQ), 80%+ renewals in integrated workflows. 
- **Life sciences challenges**: Downsell pressure persists, but 2026 outlook cautious due to macro uncertainty. 
- **Agency partnerships**: LiveRamp integration enables self-serve audience targeting, Bombora ecosystem expands B2B reach. 
- **AI investments**: 2026 roadmap includes purpose-built AI tools for data activation and measurement.

Definitive Healthcare Corp. (DH) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

DH

DH fundamentals

You can ask Aime